Rocket Pharmaceuticals (RCKTW) Financials

$0.05 -0.02 (-27.64%)

As of 04/25/2025 03:57 PM Eastern

Annual Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-222	-246	-259
Consolidated Net Income / (Loss)	-222	-246	-259
Net Income / (Loss) Continuing Operations	-222	-256	-267
Total Pre-Tax Income	-222	-256	-267
Total Operating Income	-224	-260	-273
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Operating Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	224	260	273
Selling, General & Admin Expense	59	73	102
Research & Development Expense	165	186	171
Total Other Income / (Expense), net	2.03	3.41	6.38
Interest Expense	1.86	1.88	1.89
Interest & Investment Income	3.89	5.29	8.27
Other Adjustments to Consolidated Net Income / (Loss)	-0.05	11	8.08
Basic Earnings per Share	($3.26)	($2.92)	($2.73)
Weighted Average Basic Shares Outstanding	68.15M	84.01M	94.81M
Diluted Earnings per Share	($3.26)	($2.92)	($2.73)
Weighted Average Diluted Shares Outstanding	68.15M	84.01M	94.81M
Weighted Average Basic & Diluted Shares Outstanding	79.35M	90.50M	106.63M

This table shows Rocket Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-58	-67	-58	-66	-62	-60	-62	-70	-67	-60
Consolidated Net Income / (Loss)	-58	-67	-58	-66	-62	-60	-62	-70	-67	-60
Net Income / (Loss) Continuing Operations	-58	-68	-61	-68	-64	-63	-65	-72	-69	-62
Total Pre-Tax Income	-58	-68	-61	-68	-64	-63	-65	-72	-69	-62
Total Operating Income	-58	-69	-62	-69	-65	-63	-67	-74	-69	-63
Total Operating Expenses	59	68	62	69	65	63	67	74	69	63
Selling, General & Admin Expense	15	19	16	17	19	22	22	27	27	25
Research & Development Expense	43	50	46	51	47	42	45	46	42	37
Total Other Income / (Expense), net	0.89	1.35	1.44	0.38	1.25	0.34	2.56	1.82	0.86	1.14
Interest Expense	0.47	0.47	0.47	0.47	0.47	0.47	0.47	0.47	0.47	0.47
Interest & Investment Income	1.35	1.82	1.91	0.85	1.72	0.81	3.03	2.29	1.33	1.62
Other Adjustments to Consolidated Net Income / (Loss)	-	-	2.42	2.68	2.28	3.28	2.76	2.24	1.85	1.22
Basic Earnings per Share	($0.87)	($0.89)	($0.73)	($0.82)	($0.75)	($0.62)	($0.66)	($0.74)	($0.71)	($0.62)
Weighted Average Basic Shares Outstanding	66.22M	68.15M	79.45M	80.47M	82.64M	84.01M	93.55M	93.75M	94.16M	94.81M
Diluted Earnings per Share	($0.87)	($0.89)	($0.73)	($0.82)	($0.75)	($0.62)	($0.66)	($0.74)	($0.71)	($0.62)
Weighted Average Diluted Shares Outstanding	66.22M	68.15M	79.45M	80.47M	82.64M	84.01M	93.55M	93.75M	94.16M	94.81M
Weighted Average Basic & Diluted Shares Outstanding	75.68M	79.35M	80.46M	80.53M	90.16M	90.50M	90.78M	90.98M	91.16M	106.63M

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-92	-85	108
Net Cash From Operating Activities	-178	-195	-210
Net Cash From Continuing Operating Activities	-178	-195	-210
Net Income / (Loss) Continuing Operations	-222	-246	-259
Consolidated Net Income / (Loss)	-222	-246	-259
Depreciation Expense	3.93	4.94	7.22
Amortization Expense	2.33	-8.01	-5.91
Non-Cash Adjustments To Reconcile Net Income	32	40	46
Changes in Operating Assets and Liabilities, net	6.02	14	1.74
Net Cash From Investing Activities	-69	-98	132
Net Cash From Continuing Investing Activities	-69	-98	132
Purchase of Property, Plant & Equipment	-8.36	-16	-5.86
Purchase of Investments	-376	-391	-246
Sale of Property, Plant & Equipment	0.00	0.00	0.14
Divestitures	43	0.00	0.00
Sale and/or Maturity of Investments	273	309	383
Other Investing Activities, net	-0.26	-0.04	0.00
Net Cash From Financing Activities	155	208	186
Net Cash From Continuing Financing Activities	155	208	186
Repurchase of Common Equity	-0.05	0.00	0.00
Issuance of Common Equity	155	206	183
Other Financing Activities, net	0.63	2.24	3.21
Cash Interest Paid	0.00	0.00	0.00

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	9.13	-56	-76	-19	181	-170	-21	3.33	27	98
Net Cash From Operating Activities	-44	-56	-58	-51	-57	-29	-57	-54	-52	-47
Net Cash From Continuing Operating Activities	-44	-56	-58	-51	-57	-29	-57	-54	-52	-47
Net Income / (Loss) Continuing Operations	-58	-67	-58	-66	-62	-60	-62	-70	-67	-60
Consolidated Net Income / (Loss)	-58	-67	-58	-66	-62	-60	-62	-70	-67	-60
Depreciation Expense	1.09	1.05	1.14	1.19	1.22	1.40	1.72	1.83	1.85	1.82
Amortization Expense	0.69	-0.40	0.54	-4.29	5.37	-9.63	0.54	-4.46	-1.31	-0.68
Non-Cash Adjustments To Reconcile Net Income	7.11	10	6.61	13	4.14	17	7.53	14	11	13
Changes in Operating Assets and Liabilities, net	4.41	0.16	-7.60	5.30	-6.00	22	-4.59	4.30	2.78	-0.75
Net Cash From Investing Activities	23	-109	-37	31	48	-141	35	56	79	-38
Net Cash From Continuing Investing Activities	23	-109	-37	31	48	-141	35	56	79	-38
Purchase of Property, Plant & Equipment	-0.50	-3.00	-3.02	-4.12	-4.66	-4.65	-2.04	-1.93	-1.59	-0.31
Purchase of Investments	-34	-199	-96	-73	-13	-209	-64	-39	-19	-124
Sale and/or Maturity of Investments	58	51	62	108	66	72	101	96	100	86
Net Cash From Financing Activities	30	108	18	0.18	189	0.39	1.18	1.53	0.18	183
Net Cash From Continuing Financing Activities	30	108	18	0.18	189	0.39	1.18	1.53	0.18	183
Issuance of Common Equity	29	108	17	-	189	0.00	0.00	-	-	183
Other Financing Activities, net	0.23	0.32	1.12	0.18	0.55	0.39	1.18	1.53	0.18	0.32

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	552	566	528
Total Current Assets	364	378	378
Cash & Equivalents	141	56	164
Short-Term Investments	216	317	209
Prepaid Expenses	7.67	5.05	5.85
Plant, Property, & Equipment, net	29	39	37
Total Noncurrent Assets	159	148	113
Long-Term Investments	43	34	0.00
Noncurrent Note & Lease Receivables	47	45	42
Goodwill	39	39	39
Intangible Assets	26	25	25
Other Noncurrent Operating Assets	3.92	4.43	6.06
Total Liabilities & Shareholders' Equity	552	566	528
Total Liabilities	62	74	64
Total Current Liabilities	39	49	41
Accounts Payable	37	46	38
Other Current Liabilities	2.51	2.72	2.86
Total Noncurrent Liabilities	23	25	24
Other Noncurrent Operating Liabilities	23	25	24
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	490	493	463
Total Preferred & Common Equity	490	493	463
Preferred Stock	0.00	0.00	0.00
Total Common Equity	490	493	463
Common Stock	1,204	1,452	1,681
Retained Earnings	-714	-959	-1,218
Treasury Stock	-0.05	0.00	0.00
Accumulated Other Comprehensive Income / (Loss)	-0.36	0.32	0.07

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	417	515	462	599	499	446	394
Total Current Assets	311	338	312	447	345	293	242
Cash & Equivalents	197	65	45	226	35	39	66
Short-Term Investments	110	267	262	212	295	240	170
Prepaid Expenses	4.60	6.95	5.03	9.69	15	14	6.09
Plant, Property, & Equipment, net	26	31	33	37	39	40	39
Total Noncurrent Assets	81	146	117	115	115	114	113
Long-Term Investments	-	29	0.00	0.00	0.00	0.00	0.00
Noncurrent Note & Lease Receivables	47	46	46	45	44	43	43
Goodwill	31	39	39	39	39	39	39
Intangible Assets	-	26	26	25	25	25	25
Other Noncurrent Operating Assets	2.83	6.17	6.25	6.00	6.66	6.39	6.21
Total Liabilities & Shareholders' Equity	417	515	462	599	499	446	394
Total Liabilities	50	56	59	58	58	62	64
Total Current Liabilities	30	31	34	33	33	38	40
Accounts Payable	28	29	31	31	30	35	37
Other Current Liabilities	2.36	2.60	2.99	2.85	2.87	2.86	2.85
Total Noncurrent Liabilities	20	25	24	24	25	24	24
Other Noncurrent Operating Liabilities	20	25	24	24	25	24	24
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	367	459	403	541	442	385	330
Total Preferred & Common Equity	367	459	403	541	442	385	330
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	367	459	403	541	442	385	330
Common Stock	1,015	1,231	1,242	1,441	1,463	1,476	1,487
Retained Earnings	-647	-772	-838	-900	-1,021	-1,091	-1,158
Accumulated Other Comprehensive Income / (Loss)	-0.60	-0.09	-0.72	-0.51	-0.14	-0.22	0.21

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-37.82%	-20.48%	-3.49%
EBIT Growth	-34.14%	-15.74%	-5.22%
NOPAT Growth	-34.14%	-15.74%	-5.22%
Net Income Growth	-31.23%	-10.70%	-5.35%
EPS Growth	-22.10%	10.43%	6.51%
Operating Cash Flow Growth	-47.03%	-9.42%	-7.60%
Free Cash Flow Firm Growth	-48.04%	3.10%	-13.10%
Invested Capital Growth	36.42%	-7.01%	8.59%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-16.06%	-1.24%	3.53%
EBIT Q/Q Growth	-12.40%	2.19%	0.21%
NOPAT Q/Q Growth	-12.40%	2.19%	0.21%
Net Income Q/Q Growth	-11.27%	2.80%	-0.26%
EPS Q/Q Growth	-6.89%	8.46%	0.00%
Operating Cash Flow Q/Q Growth	-16.39%	12.04%	-9.16%
Free Cash Flow Firm Q/Q Growth	-32.85%	23.37%	-9.12%
Invested Capital Q/Q Growth	48.10%	-19.45%	-3.41%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	99.80%	95.84%	96.97%
Interest Burden Percent	99.10%	98.69%	97.66%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-46.98%	-50.01%	-54.14%
Cash Return on Invested Capital (CROIC)	-232.14%	-201.99%	-227.30%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-46.98%	-50.01%	-54.14%
Return on Equity Simple (ROE_SIMPLE)	-45.31%	-49.86%	-55.86%
Net Operating Profit after Tax (NOPAT)	-157	-182	-191
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-16.44%	-15.79%	-17.28%
Return On Investment Capital (ROIC_SIMPLE)	-32.07%	-36.90%	-41.28%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-224	-260	-273
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-218	-263	-272
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.02	5.49	2.47
Price to Tangible Book Value (P/TBV)	3.49	6.31	2.87
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.01	27.41	8.51
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.83	-0.82	-0.82
Leverage Ratio	1.11	1.14	1.14
Compound Leverage Factor	1.10	1.12	1.12
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	11.86	18.79	6.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.29	7.80	9.30
Quick Ratio	9.10	7.69	9.15
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-181	-175	-198
Operating Cash Flow to CapEx	-2,131.40%	-1,185.91%	-3,662.02%
Free Cash Flow to Firm to Interest Expense	-97.25	-93.57	-105.21
Operating Cash Flow to Interest Expense	-95.67	-103.96	-111.20
Operating Cash Flow Less CapEx to Interest Expense	-100.16	-112.72	-114.24
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	90	84	91
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	24	-6.31	7.19
Enterprise Value (EV)	1,081	2,295	774
Market Capitalization	1,481	2,702	1,146
Book Value per Share	$6.47	$5.46	$5.08
Tangible Book Value per Share	$5.61	$4.75	$4.38
Total Capital	490	493	463
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-400	-407	-372
Capital Expenditures (CapEx)	8.36	16	5.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-32	-43	-35
Debt-free Net Working Capital (DFNWC)	325	330	337
Net Working Capital (NWC)	325	330	337
Net Nonoperating Expense (NNE)	65	64	68
Net Nonoperating Obligations (NNO)	-400	-409	-372
Total Depreciation and Amortization (D&A)	6.27	-3.07	1.31
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.26)	($2.92)	($2.73)
Adjusted Weighted Average Basic Shares Outstanding	68.15M	84.01M	94.81M
Adjusted Diluted Earnings per Share	($3.26)	($2.92)	($2.73)
Adjusted Weighted Average Diluted Shares Outstanding	68.15M	84.01M	94.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	79.35M	90.50M	106.63M
Normalized Net Operating Profit after Tax (NOPAT)	-157	-182	-191
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-120.49	-138.48	-144.86
NOPAT to Interest Expense	-84.34	-96.94	-101.40
EBIT Less CapEx to Interest Expense	-124.97	-147.25	-147.90
NOPAT Less CapEx to Interest Expense	-88.83	-105.71	-104.44
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.02%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-16.24%	-78.87%	-48.76%	-37.54%	-3.75%	-4.50%	-7.60%	-6.23%	-17.07%	13.92%
EBIT Growth	-17.81%	-55.83%	-46.12%	-26.83%	-11.87%	8.40%	-8.33%	-7.21%	-6.11%	0.92%
NOPAT Growth	-17.81%	-55.83%	-46.12%	-26.83%	-11.87%	8.40%	-8.33%	-7.21%	-6.11%	0.92%
Net Income Growth	-15.24%	-50.80%	-35.72%	-20.77%	-7.17%	10.59%	-6.38%	-6.00%	-7.79%	-1.12%
EPS Growth	-10.13%	-30.88%	-8.96%	1.20%	13.79%	30.34%	9.59%	9.76%	5.33%	0.00%
Operating Cash Flow Growth	-59.99%	-81.06%	-46.75%	-30.30%	-30.30%	47.63%	1.22%	-5.81%	8.83%	-60.00%
Free Cash Flow Firm Growth	3.55%	-99.55%	-52.95%	-112.58%	-137.03%	47.52%	16.58%	20.91%	56.38%	-34.46%
Invested Capital Growth	-5.33%	36.42%	39.15%	44.63%	70.97%	-7.01%	12.50%	10.30%	-9.44%	8.59%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-8.55%	-20.67%	11.39%	-18.73%	18.12%	-21.54%	-1.06%	-17.22%	9.76%	10.64%
EBIT Q/Q Growth	-7.89%	-18.11%	9.97%	-10.55%	4.84%	3.29%	-6.47%	-9.41%	5.82%	9.69%
NOPAT Q/Q Growth	-7.89%	-18.11%	9.97%	-10.55%	4.84%	3.29%	-6.47%	-9.41%	5.82%	9.69%
Net Income Q/Q Growth	-6.17%	-15.53%	12.57%	-12.63%	5.79%	3.62%	-4.01%	-12.23%	4.20%	9.58%
EPS Q/Q Growth	-4.82%	-2.30%	17.98%	-12.33%	8.54%	17.33%	-6.45%	-12.12%	4.05%	12.68%
Operating Cash Flow Q/Q Growth	-12.35%	-27.73%	-2.75%	11.62%	-12.34%	48.66%	-93.79%	5.33%	3.20%	9.91%
Free Cash Flow Firm Q/Q Growth	-2.61%	-92.93%	1.44%	-8.95%	-14.41%	57.29%	-51.22%	-3.30%	36.90%	-31.67%
Invested Capital Q/Q Growth	-8.37%	48.10%	9.80%	-2.94%	8.32%	-19.45%	30.69%	-4.84%	-11.06%	-3.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.27%	98.52%	96.02%	96.08%	96.45%	94.80%	95.74%	96.88%	97.30%	98.01%
Interest Burden Percent	98.48%	98.04%	97.68%	99.45%	98.09%	99.46%	96.20%	97.53%	98.77%	98.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-46.75%	-46.98%	-54.13%	-62.86%	-55.63%	-50.01%	-55.38%	-64.31%	-59.27%	-54.14%
Cash Return on Invested Capital (CROIC)	-218.11%	-232.14%	-233.82%	-259.54%	-278.04%	-201.99%	-188.30%	-197.02%	-183.66%	-227.30%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-46.75%	-46.98%	-54.13%	-62.86%	-55.63%	-50.01%	-55.38%	-64.31%	-59.27%	-54.14%
Return on Equity Simple (ROE_SIMPLE)	-54.28%	0.00%	-51.70%	-61.67%	-46.69%	0.00%	-56.47%	-65.84%	-78.26%	0.00%
Net Operating Profit after Tax (NOPAT)	-41	-48	-44	-48	-46	-44	-47	-52	-49	-44
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.62%	-4.66%	-4.19%	-5.59%	-4.33%	-3.80%	-4.31%	-6.16%	-5.39%	-4.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.88%	-	-	-	-8.99%	-	-	-	-9.47%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-58	-69	-62	-69	-65	-63	-67	-74	-69	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-57	-68	-61	-72	-59	-72	-65	-76	-69	-62
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.87	3.02	2.96	3.97	3.05	5.49	5.50	5.08	5.10	2.47
Price to Tangible Book Value (P/TBV)	3.13	3.49	3.45	4.73	3.46	6.31	6.44	6.10	6.33	2.87
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.30	12.01	10.11	13.47	11.67	27.41	18.87	15.84	15.35	8.51
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.85	-0.83	-0.81	-0.79	-0.82	-0.82	-0.77	-0.74	-0.77	-0.82
Leverage Ratio	1.11	1.11	1.11	1.13	1.12	1.14	1.13	1.15	1.14	1.14
Compound Leverage Factor	1.09	1.09	1.09	1.12	1.10	1.13	1.08	1.12	1.13	1.12
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	10.84	12.79	12.81	14.00	15.53	19.94	22.59	15.70	11.69	7.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.31	9.29	10.83	9.09	13.35	7.80	10.47	7.79	6.05	9.30
Quick Ratio	10.16	9.10	10.61	8.94	13.06	7.69	10.02	7.42	5.89	9.15
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-72	-71	-78	-89	-38	-60	-61	-39	-51
Operating Cash Flow to CapEx	-8,719.48%	-1,865.50%	-1,909.12%	-1,234.98%	-1,227.67%	-631.35%	-2,793.91%	-2,788.76%	-3,281.05%	-15,191.59%
Free Cash Flow to Firm to Interest Expense	-80.69	-154.68	-152.44	-166.09	-189.63	-80.82	-126.36	-130.53	-82.36	-107.98
Operating Cash Flow to Interest Expense	-94.32	-119.70	-122.99	-108.69	-121.85	-62.42	-120.71	-114.27	-110.62	-99.24
Operating Cash Flow Less CapEx to Interest Expense	-95.40	-126.12	-129.43	-117.50	-131.78	-72.31	-125.03	-118.37	-113.99	-99.90
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	61	90	99	96	104	84	111	106	94	91
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-3.42	24	28	30	43	-6.31	12	9.88	-9.81	7.19
Enterprise Value (EV)	748	1,081	999	1,292	1,213	2,295	2,099	1,676	1,445	774
Market Capitalization	1,054	1,481	1,359	1,599	1,650	2,702	2,429	1,955	1,680	1,146
Book Value per Share	$5.56	$6.47	$5.78	$5.01	$6.72	$5.46	$4.72	$4.24	$3.62	$5.08
Tangible Book Value per Share	$5.10	$5.61	$4.97	$4.20	$5.92	$4.75	$4.03	$3.53	$2.92	$4.38
Total Capital	367	490	459	403	541	493	442	385	330	463
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-307	-400	-360	-307	-437	-407	-330	-279	-236	-372
Capital Expenditures (CapEx)	0.50	3.00	3.02	4.12	4.66	4.65	2.04	1.93	1.59	0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-32	-24	-29	-24	-43	-18	-24	-34	-35
Debt-free Net Working Capital (DFNWC)	281	325	307	278	413	330	312	255	202	337
Net Working Capital (NWC)	281	325	307	278	413	330	312	255	202	337
Net Nonoperating Expense (NNE)	17	18	15	18	16	15	15	18	18	16
Net Nonoperating Obligations (NNO)	-307	-400	-360	-307	-437	-409	-330	-279	-236	-372
Total Depreciation and Amortization (D&A)	1.78	0.65	1.67	-3.10	6.59	-8.23	2.25	-2.63	0.54	1.14
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.87)	($0.89)	($0.73)	($0.82)	($0.75)	($0.62)	($0.66)	($0.74)	($0.71)	($0.62)
Adjusted Weighted Average Basic Shares Outstanding	66.22M	68.15M	79.45M	80.47M	82.64M	84.01M	93.55M	93.75M	94.16M	94.81M
Adjusted Diluted Earnings per Share	($0.87)	($0.89)	($0.73)	($0.82)	($0.75)	($0.62)	($0.66)	($0.74)	($0.71)	($0.62)
Adjusted Weighted Average Diluted Shares Outstanding	66.22M	68.15M	79.45M	80.47M	82.64M	84.01M	93.55M	93.75M	94.16M	94.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	75.68M	79.35M	80.46M	80.53M	90.16M	90.50M	90.78M	90.98M	91.16M	106.63M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-48	-44	-48	-46	-44	-47	-52	-49	-44
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-125.78	-147.61	-132.89	-146.92	-139.51	-134.64	-143.05	-156.50	-147.40	-132.55
NOPAT to Interest Expense	-88.05	-103.33	-93.03	-102.84	-97.66	-94.25	-100.13	-109.55	-103.18	-92.78
EBIT Less CapEx to Interest Expense	-126.86	-154.03	-139.34	-155.72	-149.43	-144.52	-147.37	-160.60	-150.77	-133.20
NOPAT Less CapEx to Interest Expense	-89.13	-109.74	-99.47	-111.64	-107.58	-104.13	-104.45	-113.65	-106.55	-93.44
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Rocket Pharmaceuticals' Financials

When does Rocket Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Rocket Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Rocket Pharmaceuticals' net income changed over the last 2 years?

Rocket Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$258.75 million in 2024, rising from -$221.86 million in 2022. The previous period was -$245.60 million in 2023.

What is Rocket Pharmaceuticals's operating income?

Rocket Pharmaceuticals's total operating income in 2024 was -$273.21 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $273.21 million

How has Rocket Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Rocket Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals' total liabilities were at $64.47 million at the end of 2024, a 12.6% decrease from 2023, and a 3.8% increase since 2022.

How much cash does Rocket Pharmaceuticals have?

In the past 2 years, Rocket Pharmaceuticals' cash and equivalents has ranged from $55.90 million in 2023 to $163.64 million in 2024, and is currently $163.64 million as of their latest financial filing in 2024.

How has Rocket Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Rocket Pharmaceuticals' book value per share changed from 6.47 in 2022 to 5.08 in 2024, a change of -21.5%.

Related Companies

This page (NASDAQ:RCKTW) was last updated on 4/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKTW) Financials

Frequently Asked Questions About Rocket Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKTW) Financials

Annual Income Statements for Rocket Pharmaceuticals

Quarterly Income Statements for Rocket Pharmaceuticals

Annual Cash Flow Statements for Rocket Pharmaceuticals

Quarterly Cash Flow Statements for Rocket Pharmaceuticals

Annual Balance Sheets for Rocket Pharmaceuticals

Quarterly Balance Sheets for Rocket Pharmaceuticals

Annual Metrics and Ratios for Rocket Pharmaceuticals

Quarterly Metrics and Ratios for Rocket Pharmaceuticals

Frequently Asked Questions About Rocket Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools